MSP-RON Signalling in Cancer: Pathogenesis and Therapeutic Potential

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2013 Jun 25

PMID 23792360

Citations 107

Authors

Hang-Ping Yao

Yong-Qing Zhou

Ruiwen Zhang

Ming-Hai Wang

Affiliations

Soon will be listed here.

Abstract

Since the discovery of MSP (macrophage-stimulating protein; also known as MST1 and hepatocyte growth factor-like (HGFL)) as the ligand for the receptor tyrosine kinase RON (also known as MST1R) in the early 1990s, the roles of this signalling axis in cancer pathogenesis has been extensively studied in various model systems. Both in vitro and in vivo evidence has revealed that MSP-RON signalling is important for the invasive growth of different types of cancers. Currently, small-molecule inhibitors and antibodies blocking RON signalling are under investigation. Substantial responses have been achieved in human tumour xenograft models, laying the foundation for clinical validation. In this Review, we discuss recent advances that demonstrate the importance of MSP-RON signalling in cancer and its potential as a therapeutic target.

Citing Articles

Gene Variants Predispose Individuals to Tetralogy of Fallot.

Feng Z, Huang X, Gao Y, Gao H, Na W, Tan C Phenomics. 2025; 4(6):548-561.

PMID: 40061823 PMC: 11889330. DOI: 10.1007/s43657-024-00175-9.

CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11.

Song X, Wei Z, Zhang C, Han D, Liu J, Song Y Mol Cancer. 2025; 24(1):53.

PMID: 39994725 PMC: 11852832. DOI: 10.1186/s12943-025-02261-6.

Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity.

Wang M, Ma Q, Suthe S, Hudson R, Pan J, Mikelis C Acta Pharmacol Sin. 2025; .

PMID: 39837982 DOI: 10.1038/s41401-024-01458-7.

Network-Based Bioinformatics Highlights Broad Importance of Human Milk Hyaluronan.

Burge K, Zhong H, Wilson A, Chaaban H Int J Mol Sci. 2024; 25(23).

PMID: 39684390 PMC: 11641400. DOI: 10.3390/ijms252312679.

RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2α pathways.

Wang K, Ye S, Jia X, Wang K, Meng X, Fei X Cell Death Dis. 2024; 15(11):844.

PMID: 39557851 PMC: 11574271. DOI: 10.1038/s41419-024-07245-w.

References

Collesi C, Santoro M, Gaudino G, Comoglio P . A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996; 16(10):5518-26. PMC: 231551. DOI: 10.1128/MCB.16.10.5518. View

Krawczyk M, Hoblinger A, Mihalache F, Grunhage F, Acalovschi M, Lammert F . Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis. 2013; 45(7):612-5. DOI: 10.1016/j.dld.2012.12.017. View

Ni S, Zhao C, Feng G, Paulson R, Correll P . A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol. 2007; 27(10):3708-15. PMC: 1899994. DOI: 10.1128/MCB.01838-06. View

Catenacci D, Cervantes G, Yala S, Nelson E, El-Hashani E, Kanteti R . RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011; 12(1):9-46. PMC: 3149873. DOI: 10.4161/cbt.12.1.15747. View

Sharma S, Zeng J, Zhuang C, Zhou Y, Yao H, Hu X . Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther. 2013; 12(5):725-36. DOI: 10.1158/1535-7163.MCT-12-1079. View

Danilkovitch-Miagkova A, Duh F, Kuzmin I, Angeloni D, Liu S, Miller A . Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc Natl Acad Sci U S A. 2003; 100(8):4580-5. PMC: 153598. DOI: 10.1073/pnas.0837136100. View

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

Santoro M, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G . Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene. 1998; 17(6):741-9. DOI: 10.1038/sj.onc.1201994. View

Sato S, Hanibuchi M, Kuramoto T, Yamamori N, Goto H, Ogawa H . Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clin Exp Metastasis. 2012; 30(3):333-44. DOI: 10.1007/s10585-012-9540-y. View

10.

Wang M, Julian F, Breathnach R, Godowski P, Takehara T, Yoshikawa W . Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem. 1997; 272(27):16999-7004. DOI: 10.1074/jbc.272.27.16999. View

11.

Liu X, Zhao L, Derose Y, Lin Y, Bieniasz M, Eyob H . Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer. 2011; 2(7):753-62. PMC: 3218405. DOI: 10.1177/1947601911421924. View

12.

Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani G . Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 2004; 64(15):5154-61. DOI: 10.1158/0008-5472.CAN-04-0600. View

13.

Zinser G, Leonis M, Toney K, Pathrose P, Thobe M, Kader S . Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006; 66(24):11967-74. DOI: 10.1158/0008-5472.CAN-06-2473. View

14.

Lee K, Park J, Khoi P, Joo Y, Lee Y, Jung Y . Upregulation of recepteur d'origine nantais tyrosine kinase and cell invasiveness via early growth response-1 in gastric cancer cells. J Cell Biochem. 2011; 113(4):1217-23. DOI: 10.1002/jcb.23454. View

15.

Umehara D, Watanabe S, Ochi H, Anai Y, Ahmed N, Kannagi M . Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease. J Virol. 2010; 84(15):7675-82. PMC: 2897631. DOI: 10.1128/JVI.00488-10. View

16.

Willett C, Smith D, Shridhar V, Wang M, Emanuel R, Patidar K . Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival. J Clin Invest. 1997; 99(12):2979-91. PMC: 508150. DOI: 10.1172/JCI119493. View

17.

Wang M, Lao W, Wang D, Luo Y, Yao H . Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther. 2007; 6(7):1121-9. DOI: 10.4161/cbt.6.7.4337. View

18.

Ma Q, Zhang K, Yao H, Zhou Y, Padhye S, Wang M . Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol. 2010; 36(6):1551-61. DOI: 10.3892/ijo_00000642. View

19.

Chan E, Peace B, Collins M, Toney-Earley K, Waltz S . Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene. 2004; 24(3):479-88. DOI: 10.1038/sj.onc.1208231. View

20.

Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S . A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994; 77(2):261-71. DOI: 10.1016/0092-8674(94)90318-2. View